Clinical Trials Browser

Phase 3 × olaparib × 1 year × Clear all

NCT03486873 2026-03-16

MK-3475-587

Phase 3 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

NCT04729387 2026-03-13

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Phase 3 Terminated

Ovarian Neoplasms

NCT05171816 2026-03-11

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)

Phase 3 Active not recruiting

110 enrolled 12 charts

Metastatic Castration-resistant Prostate Cancer

NCT02446600 2026-03-05

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 3 Active not recruiting

579 enrolled 17 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04884360 2026-03-02

MONO-OLA1

Phase 3 Active not recruiting

Ovarian Neoplasms

NCT06915025 2026-02-27

OVATION-3

Phase 3 Recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03976323 2026-02-25

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

Phase 3 Completed

1,003 enrolled 23 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma

NCT03976362 2026-02-25

KEYLYNK-008

Phase 3 Completed

851 enrolled 25 charts

Carcinoma

NCT02032823 2026-02-17

OlympiA

Phase 3 Active not recruiting

1,836 enrolled 20 charts 1 FDA

Breast Neoplasms

NCT02000622 2026-02-13

OlympiAD

Phase 3 Completed

302 enrolled 26 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT04421963 2026-01-21

ROSY-O

Phase 3 Active not recruiting

BreastGynecologic

Breast Neoplasms, Neoplasms, Ovarian Neoplasms

NCT06712472 2026-01-20

RAINBO-RED

Phase 3 Recruiting

Endometrial Neoplasms

NCT06580314 2026-01-14

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Phase 3 Recruiting

Ovarian Neoplasms

NCT04269200 2025-12-23

DUO-E

Phase 3 Active not recruiting

805 enrolled 18 charts 1 FDA

Endometrial Neoplasms

NCT06112379 2025-12-17

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Phase 3 Active not recruiting

Breast Neoplasms

NCT03784014 2025-12-11

MULTISARC

Phase 3 Active not recruiting

Neoplasm Metastasis, Sarcoma

NCT01844986 2025-12-10

SOLO-1

Phase 3 Active not recruiting

450 enrolled 18 charts 1 FDA

Pathologic Complete Response, Ovarian Neoplasms

NCT03740165 2025-10-22

KEYLYNK-001

Phase 3 Active not recruiting

1,367 enrolled 29 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT04380636 2025-08-17

MK-7339-012

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01874353 2025-08-03

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Phase 3 Active not recruiting

327 enrolled 21 charts 1 FDA

Ovarian Neoplasms

NCT04624204 2025-07-02

MK 7339-013

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT03834519 2025-05-18

KEYLYNK-010

Phase 3 Completed

793 enrolled 23 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms